Tada Yoshifumi, Ono Nobuyuki, Koarada Syuichi
Department of Rheumatology, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
Case Rep Rheumatol. 2021 Feb 5;2021:8876847. doi: 10.1155/2021/8876847. eCollection 2021.
Biological disease-modifying antirheumatic drugs (bDMARDs) are very effective for treating rheumatoid arthritis (RA). However, they sometimes induce adverse events such as psoriasis-like skin lesions. We describe psoriasis-like skin lesions that developed simultaneously with an RA flare in patient 1 during treatment with abatacept and in patient 2 soon after starting certolizumab pegol. The skin lesions persisted in patient 2 despite stopping certolizumab. Baricitinib was initiated because of RA flare and resulted in immediate beneficial effects on arthritis as well as skin lesions. The RA went into remission in both patients, and the psoriasis-like skin lesions disappeared within four weeks (patient 1) and three months (patient 2).
生物性改善病情抗风湿药(bDMARDs)对治疗类风湿关节炎(RA)非常有效。然而,它们有时会引发不良事件,如银屑病样皮肤病变。我们描述了在患者1使用阿巴西普治疗期间以及患者2开始使用赛妥珠单抗培戈后不久,银屑病样皮肤病变与RA病情发作同时出现的情况。尽管患者2停用了赛妥珠单抗,但皮肤病变仍持续存在。由于RA病情发作,开始使用巴瑞替尼,结果对关节炎以及皮肤病变立即产生了有益效果。两名患者的RA均缓解,银屑病样皮肤病变在4周内(患者1)和3个月内(患者2)消失。